Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.55 |
| ▸ | GRM8 | O00222 | 4/20 | 0.53 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.53 |
| ▸ | GRM6 | O15303 | 3/20 | 0.52 |
| ▸ | ACP3 | P15309 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16293830 | 1.00 | KMO (0.55) | KMOGRM8GRM4GRM6ACP3 | |
| SCHEMBL3310878 | 1.00 | KMO (0.55) | KMOGRM8GRM4GRM6ACP3 | |
| SCHEMBL3859569 | 1.00 | KMO (0.55) | KMOGRM8GRM4GRM6ACP3 | |
| Hydrochloric Acid SCHEMBL3812830 | 0.98 | KMO (0.53) | KMOGRM8GRM4GRM6ACP3 | |
| Hydrochloric Acid SCHEMBL3812833 | 0.98 | KMO (0.53) | KMOGRM8GRM4GRM6ACP3 | |
| SCHEMBL9263216 | 0.88 | TSHR (0.51) | KMOGRM8GRM4GRM6ACP3 | |
| SCHEMBL666558 | 0.85 | GRM8 (0.54) | KMOGRM8GRM4GRM6ACP3 | |
| SCHEMBL16933041 | 0.84 | ACP3 (0.54) | KMOGRM8GRM4GRM6ACP3 | |
| SCHEMBL665345 | 0.83 | MEN1 (0.51) | KMOGRM8GRM4GRM6SMN1; SMN2 | |
| SCHEMBL8297473 | 0.83 | MEN1 (0.51) | KMOGRM8GRM4GRM6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-28 | — | — | US | disclosed |
| EP-3008052-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-04-20 | — | — | EP | disclosed |
| WO-2014201073-A9 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-08 | — | — | WO | disclosed |
| CN-102317269-B | Novel amino aza heterocyclic carboxamides | MERCK PATENT GMBH | 2015-06-17 | — | — | CN | disclosed |
| US-9040560-B2 | Amino azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-9040560-B2 | Amino azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-9040560-B2 | Amino azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| WO-2014201073-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-18 | — | — | WO | disclosed |
| EP-2396307-B1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2014-10-15 | — | — | EP | disclosed |
| CN-1324348-A | TAN-1057 derivatives | BAYER AG (DE) | 2001-11-28 | — | — | CN | disclosed |
| EP-1153014-A2 | BETA-ALANINE DERIVATIVES | MERCK PATENT GmbH (DE) | 2001-11-14 | — | — | EP | disclosed |
| EP-1117652-A1 | TAN-1057 DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2001-07-25 | — | — | EP | disclosed |
| CN-1267306-A | Cyclopeptide derivs. as adhesion inhibitors | MERCK PATENT GMBH (DE) | 2000-09-20 | — | — | CN | disclosed |
| WO-2000048996-A2 | β-ALANINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2000-08-24 | — | — | WO | disclosed |
| WO-2000012484-A1 | TAN-1057 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-03-09 | — | — | WO | disclosed |
| US-5280027-A | Quinazoline containing compound | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-18 | — | — | US | disclosed |
| EP-0459730-A2 | Anti-tumour compounds | ZENECA LIMITED (GB) | 1991-12-04 | — | — | EP | disclosed |
| WO-1990002112-A1 | SUBSTITUTED ARYL UREAS AS HIGH POTENCY SWEETENERS | THE NUTRASWEET COMPANY (US) | 1990-03-08 | — | — | WO | disclosed |
| EP-0355819-A1 | Substituted aryl ureas as high potency sweeteners | THE NUTRASWEET COMPANY (a Delaware corporation) (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | KMO 3780/4885GRM8 4701/4885GRM4 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.